Samstag, 4. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
IMvigor011

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Rekrutierend

NCT-Nummer:
NCT04660344

Studienbeginn:
Mai 2021

Letztes Update:
22.04.2024

Wirkstoff:
Atezolizumab

Indikation (Clinical Trials):
Urinary Bladder Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Hoffmann-La Roche

Collaborator:
-

Studienleiter

Clinical Trials
Study Director
Hoffmann-La Roche

Kontakt

Reference Study ID Number: BO42843 https://forpatients.roche.com/
Kontakt:
Phone: 888-662-6728 (U.S. and Canada)
E-Mail: global.rochegenentechtrials@roche.com
» Kontaktdaten anzeigen

Studienlocations
(3 von 209)

Universitätsklinikum Düsseldorf; Urologische Klinik
40225 Düsseldorf
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie
06120 Halle (Saale)
(Sachsen-Anhalt)
GermanyRekrutierend» Google-Maps
Universitätsklinikum der Ruhr-Universität Bochum, Marien-Hospital Herne, Urologische Klinik
44625 Herne
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Universitätsklinikum Jena, Urologische Klinik und Poliklinik
07743 Jena
(Thüringen)
GermanyRekrutierend» Google-Maps
Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik
81675 München
(Bayern)
GermanyRekrutierend» Google-Maps
Universitätsklinikum Münster, Klinik für Urologie und Kinderurologie
48149 Münster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Universitätsklinikum Tübingen; Klinik für Urologie
72076 Tübingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Universitätsklinikum Ulm; Klinik für Urologie
89081 Ulm
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Universitätsklinikum Würzburg; Klinik und Poliklinik für Urologie und Kinderurologie
97080 Würzburg
(Bayern)
GermanyRekrutierend» Google-Maps
Rocky Mountain Cancer Center - Denver
80120 Littleton
United StatesRekrutierend» Google-Maps
Woodlands Medical Specialists, P.A.
32503 Pensacola
United StatesZurückgezogen» Google-Maps
Cancer Care Centers of Brevard
32955 Rockledge
United StatesZurückgezogen» Google-Maps
Wake Forest Baptist Medical Center
27157 Winston-Salem
United StatesRekrutierend» Google-Maps
Allegheny General Hospital
15212 Pittsburgh
United StatesRekrutierend» Google-Maps
Texas Oncology Cancer Center
78731 Austin
United StatesZurückgezogen» Google-Maps
Texas Oncology-Medical City Dallas
75230 Dallas
United StatesZurückgezogen» Google-Maps
Texas Oncology-Denton South
76201 Denton
United StatesZurückgezogen» Google-Maps
Texas Oncology-Fort Worth 12th Ave
76104 Fort Worth
United StatesZurückgezogen» Google-Maps
Texas Oncology - Houston (Gessner)
77024 Houston
United StatesZurückgezogen» Google-Maps
Texas Oncology - Willowbrook
77070 Houston
United StatesZurückgezogen» Google-Maps
Texas Oncology P.A. (McKinney)
75071 McKinney
United StatesZurückgezogen» Google-Maps
Instituto Alexander Fleming
1426 Buenos Aires
ArgentinaRekrutierend» Google-Maps
Cemic; Oncologia Clinica
C1431FWN Buenos Aires
ArgentinaZurückgezogen» Google-Maps
Oncocentro Serviços Medicos E Hospitalares Ltda
60135-237 Fortaleza
BrazilRekrutierend» Google-Maps
Crio - Centro Regional Integrado de Oncologia
60336-232 Fortaleza
BrazilZurückgezogen» Google-Maps
CETUS Hospital Dia Oncologia
38082-049 Uberaba
BrazilRekrutierend» Google-Maps
Hospital Erasto Gaertner
81520-060 Curitiba
BrazilRekrutierend» Google-Maps
Hospital Moinhos de Vento
90035-000 Porto Alegre
BrazilRekrutierend» Google-Maps
Hospital Nossa Senhora da Conceicao
90040-373 Porto Alegre
BrazilRekrutierend» Google-Maps
Hospital Sao Lucas - PUCRS
90610-000 Porto Alegre
BrazilRekrutierend» Google-Maps
*X*Fundação Pio XII Hospital de Câncer de Barretos
14784-400 Barretos
BrazilRekrutierend» Google-Maps
Instituto do Cancer do Estado de Sao Paulo - ICESP
01246-000 Sao Paulo
BrazilRekrutierend» Google-Maps
Hospital Alemao Oswaldo Cruz; Pesquisa Clinica
01323-020 Sao Paulo
BrazilRekrutierend» Google-Maps
Beneficencia Portuguesa de Sao Paulo
01321-00 São Paulo
BrazilRekrutierend» Google-Maps
Sunnybrook Research Institute
M4N 3M5 Toronto
CanadaZurückgezogen» Google-Maps
Princess Margaret Cancer Center
M5G 1Z5 Toronto
CanadaZurückgezogen» Google-Maps
Peking University First Hospital
100034 Beijing City
ChinaAktiv, nicht rekrutierend» Google-Maps
Friendship Hospital, Capital Medical University
100050 Beijing
ChinaRekrutierend» Google-Maps
the First Hospital of Jilin University
130021 Changchun
ChinaRekrutierend» Google-Maps
Hu Nan Provincial Cancer Hospital
410006 Changsha
ChinaRekrutierend» Google-Maps
The First Affiliated Hospital of Fujian Medical University
350005 Fu Zhou
ChinaRekrutierend» Google-Maps
Fujian Medical University Union Hospital
350001 Fuzhou City
ChinaRekrutierend» Google-Maps
The First Affiliated Hospital of Guangzhou Medical University
510120 Guangzhou
ChinaRekrutierend» Google-Maps
Harbin Medical University Cancer Hospital
150081 Harbin
ChinaZurückgezogen» Google-Maps
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
210008 Nanjing City
ChinaAktiv, nicht rekrutierend» Google-Maps
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
210029 Nanjing City
ChinaAktiv, nicht rekrutierend» Google-Maps
Huashan Hospital Affiliated to Fudan University
200040 Shanghai City
ChinaZurückgezogen» Google-Maps
Fudan University Shanghai Cancer Center
200120 Shanghai City
ChinaRekrutierend» Google-Maps
Zhongshan Hospital Fudan University
200032 Shanghai
ChinaRekrutierend» Google-Maps
Liaoning cancer Hospital & Institute
110042 Shenyang
ChinaRekrutierend» Google-Maps
The 2nd Hospital of Tianjin Medical University; Department of Urology
300211 Tianjin
ChinaAktiv, nicht rekrutierend» Google-Maps
Xinjiang Medical University Cancer Hospital
830011 Urumqi City
ChinaZurückgezogen» Google-Maps
The First Affiliated Hospital of Xiamen University
361003 Xiamen
ChinaZurückgezogen» Google-Maps
Instituto Cancerologia Medellin; Clinica Las Americas
050024 Medellin
ColombiaRekrutierend» Google-Maps
Fakultni nemocnice Olomouc; Onkologicka klinika
779 00 Olomouc
CzechiaRekrutierend» Google-Maps
Fakultni Thomayerova nemocnice; Onkologicka klinika 1. LF UK a FTN
140 59 Praha 4 - Krc
CzechiaRekrutierend» Google-Maps
Fakultni nemocnice v Motole; Onkologicka klinika 2. LF UK a FN Motol
150 06 Praha 5
CzechiaRekrutierend» Google-Maps
ICO Paul Papin; Oncologie Medicale.
49055 Angers
FranceRekrutierend» Google-Maps
Institut Sainte Catherine;Recherche Clinique
84918 Avignon
FranceRekrutierend» Google-Maps
CHU Besançon - Hôpital Jean Minjoz
25030 Besançon Cedex
FranceZurückgezogen» Google-Maps
Hopital Saint Andre
33075 Bordeaux
FranceAktiv, nicht rekrutierend» Google-Maps
Centre Léon Bérard; Centre régional; le cancer Rhône-Alpes
69373 Lyon
FranceRekrutierend» Google-Maps
Centre D'Oncologie de Gentilly; Oncology
54100 Nancy
FranceRekrutierend» Google-Maps
Institut Mutualiste Montsouris; Oncologie
75674 Paris
FranceRekrutierend» Google-Maps
Institut Gustave Roussy; Departement Oncologie Medicale
94805 Villejuif
FranceRekrutierend» Google-Maps
Alexandras General Hospital of Athens; Oncology Department
115 28 Athens
GreeceRekrutierend» Google-Maps
Attikon University General Hospital
124 62 Chaidari
GreeceRekrutierend» Google-Maps
University Hospital of Larissa;Department of Medical Oncology
411 10 Larissa
GreeceRekrutierend» Google-Maps
University Hospital of Patras Medical Oncology
265 04 Patras
GreeceRekrutierend» Google-Maps
Queen Mary Hospital; Dept. Of Haematology & Oncology
Hong Kong
Hong KongRekrutierend» Google-Maps
Tuen Mun Hospital; Clinical Oncology
Hong Kong
Hong KongRekrutierend» Google-Maps
St Vincents University Hospital
D04 T6F4 Dublin
IrelandRekrutierend» Google-Maps
Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital; Oncology Day Unit
D24 NR0A Dublin
IrelandRekrutierend» Google-Maps
Rambam Medical Center; Oncology
3109601 Haifa
IsraelAbgeschlossen» Google-Maps
Hadassah Ein Karem Hospital; Oncology Dept
9112000 Jerusalem
IsraelRekrutierend» Google-Maps
Rabin Medical Center; Oncology Dept
4910000 Petah Tikva
IsraelZurückgezogen» Google-Maps
Tel Aviv Sourasky Medical Ctr; Oncology
6423906 Tel Aviv
IsraelAktiv, nicht rekrutierend» Google-Maps
Azienda Ospedaliera di Rilievo Nazionale "Antonio Cardarelli", Day Hospital Oncologico
80131 Napoli
ItalyRekrutierend» Google-Maps
ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico
80131 Napoli
ItalyRekrutierend» Google-Maps
AZ.Osp S. Orsola ? Malpighi-Reparto di Oncologia Medica
40138 Bologna
ItalyRekrutierend» Google-Maps
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
47014 Meldola
ItalyRekrutierend» Google-Maps
Policlinico Universitario "Agostino Gemelli"; U.O.C. Oncologia Medica
00168 Roma
ItalyRekrutierend» Google-Maps
A.O. Universitaria S. Martino Di Genova
16132 Genova
ItalyRekrutierend» Google-Maps
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
20133 Milano
ItalyRekrutierend» Google-Maps
A.O. UNIVERSITARIA S. LUIGI GONZAGA; Oncologia Medica
10043 Orbassano
ItalyRekrutierend» Google-Maps
Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia
52100 Arezzo
ItalyRekrutierend» Google-Maps
Azienda Ospedaliera Santa Maria di Terni
20089 Terni
ItalyRekrutierend» Google-Maps
IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II
35128 Padova
ItalyRekrutierend» Google-Maps
Toho University Sakura Medical Center
285-8741 Chiba
JapanRekrutierend» Google-Maps
Hiroshima City Hiroshima Citizens Hospital
730-8518 Hiroshima
JapanRekrutierend» Google-Maps
National Hospital Organization Hokkaido Cancer Center
003-0804 Hokkaido
JapanRekrutierend» Google-Maps
University of Tsukuba Hospital
305-8576 Ibaraki
JapanRekrutierend» Google-Maps
Iwate Medical University Hospital
028-3695 Iwate
JapanRekrutierend» Google-Maps
St. Marianna University Hospital
216-8511 Kanagawa
JapanRekrutierend» Google-Maps
Okayama University Hospital
700-8558 Okayama
JapanRekrutierend» Google-Maps
Osaka International Cancer Institute
541-8567 Osaka
JapanRekrutierend» Google-Maps
Saitama Medical University International Medical Center
350-1298 Saitama
JapanRekrutierend» Google-Maps
Tokushima University Hospital
770-8503 Tokushima
JapanRekrutierend» Google-Maps
National Cancer Center Hospital
104-0045 Tokyo
JapanRekrutierend» Google-Maps
The Cancer Institute Hospital of JFCR
135-8550 Tokyo
JapanRekrutierend» Google-Maps
Kyungpook National University Chilgok Hospital
41404 Daegu
Korea, Republic ofAbgeschlossen» Google-Maps
National Cancer Center
10408 Goyang-si
Korea, Republic ofRekrutierend» Google-Maps
Seoul National University Hospital
03080 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Asan Medical Center
05505 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Samsung Medical Center
06351 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Centro Medico Nacional Siglo Xxi - Imss; Hospital de Oncologia
06720 Mexico City
MexicoRekrutierend» Google-Maps
Inst. Nacional de La Nutricion Salvador Zubiran; Oncology
14000 Mexico City
MexicoRekrutierend» Google-Maps
CUAN Hospital; Centro de Urologia Avnazada del Noreste
66278 San Pedro Garza García
MexicoRekrutierend» Google-Maps
Instituto Nacional de Cancerologia; Oncology
14080 Mexico City
MexicoRekrutierend» Google-Maps
Wojewódzki Szpital Specjalistyczny im. M. Kopernika w ?odzi
93-513 ?ód?
PolandRekrutierend» Google-Maps
Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny
36-200 Brzozów
PolandAbgeschlossen» Google-Maps
Szpital Uniwersytecki Nr 1 im. Dr. Antoniego Jurasza w Bydgoszczy; Klinika Urologii i Onkologicznej
85-094 Bydgoszcz
PolandZurückgezogen» Google-Maps
Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu; Oddzia? Chemioterapii
60-569 Pozna?
PolandRekrutierend» Google-Maps
Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o.
04-073 Warszawa
PolandRekrutierend» Google-Maps
Dolno?l?skie Centrum Onkologii, Pulmonologii i Hematologii
53-413 Wroc?aw
PolandRekrutierend» Google-Maps
FSBI National Medical Research Radiological Center; A. TSYB MEDICAL RADIOLOGICAL RESEARCH CENTER
249036 Obninsk
Russian FederationZurückgezogen» Google-Maps
St-Petersburg Regional Oncology Dispensary; Oncology
188663 Kuzmolovo
Russian FederationRekrutierend» Google-Maps
FSBSI ?N. N. Blokhin Russian Cancer Research Center?
115478 Moscow
Russian FederationZurückgezogen» Google-Maps
Russian Scientific Center of Roentgenoradiology
117997 Moscow
Russian FederationZurückgezogen» Google-Maps
Privolzhsk Regional Medical Center
603001 Nizhny Novgorod
Russian FederationRekrutierend» Google-Maps
FSI Russian Centre of Radiology and Surgical Technologies
197758 Saint-Petersburg
Russian FederationRekrutierend» Google-Maps
Ivanovo Regional Oncology Dispensary
153040 Ivanovo
Russian FederationAktiv, nicht rekrutierend» Google-Maps
Murmansk Regional Clinical Hospital named after P.A. Bayandin
183047 Murmansk
Russian FederationAktiv, nicht rekrutierend» Google-Maps
National University Hospital; National University Cancer Institute, Singapore (NCIS)
119228 Singapore
SingaporeRekrutierend» Google-Maps
National Cancer Centre; Medical Oncology
168583 Singapore
SingaporeRekrutierend» Google-Maps
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
8208 Sabadell
SpainRekrutierend» Google-Maps
Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
39008 Santander
SpainRekrutierend» Google-Maps
Hospital Universitario Reina Sofia; Servicio de Oncologia
14004 Córdoba
SpainRekrutierend» Google-Maps
Hospital de Donostia; Servicio de Oncologia Medica
20080 San Sebastian
SpainRekrutierend» Google-Maps
Complejo Hospitalario Universitario Insular?Materno Infantil; Servicio de Oncologia
35016 Las Palmas de Gran Canaria
SpainRekrutierend» Google-Maps
Hospital Universitari Vall d'Hebron; Oncology
08035 Barcelona
SpainRekrutierend» Google-Maps
Hospital Clínic i Provincial; Servicio de Oncología
08036 Barcelona
SpainRekrutierend» Google-Maps
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
08041 Barcelona
SpainRekrutierend» Google-Maps
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
28007 Madrid
SpainZurückgezogen» Google-Maps
Centro Oncologico MD Anderson Internacional; Servicio de Oncologia
28033 Madrid
SpainZurückgezogen» Google-Maps
Hospital Ramon y Cajal; Servicio de Oncologia
28034 Madrid
SpainRekrutierend» Google-Maps
Hospital Clinico San Carlos; Servicio de Oncologia
28040 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario 12 de Octubre; Servicio de Oncologia
28041 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario La Paz; Servicio de Oncologia
28046 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario Virgen del Rocio; Servicio de Oncologia
41013 Sevilla
SpainRekrutierend» Google-Maps
Instituto Valenciano Oncologia; Oncologia Medica
46009 Valencia
SpainRekrutierend» Google-Maps
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
46010 Valencia
SpainRekrutierend» Google-Maps
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology
01230 Adana
TurkeyRekrutierend» Google-Maps
Ankara University Faculty of Medicine Cebeci Hospital
06700 Ankara
TurkeyRekrutierend» Google-Maps
Ankara City Hospital; Oncology
06800 Ankara
TurkeyRekrutierend» Google-Maps
Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji
34147 Bakirkoy / Istanbul
TurkeyRekrutierend» Google-Maps
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
22030 Edirne
TurkeyRekrutierend» Google-Maps
Istanbul University Cerrahpasa Faculty of Medicine
34098 Istanbul
TurkeyRekrutierend» Google-Maps
Medeniyet University Goztepe Training and Research Hospital.
34722 Kadiköy
TurkeyRekrutierend» Google-Maps
Medikal Park Izmir Hospital
35575 Kar??yaka
TurkeyAktiv, nicht rekrutierend» Google-Maps
Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval Department of Urology #4
61037 Kharkiv
UkraineRekrutierend» Google-Maps
ME Dnipropetrovsk Regional Clinical Hospital n.a. I.I Mechnykov Dnipropetrovsk Regional Council
49005 Dnipro
UkraineRekrutierend» Google-Maps
Lviv Regional Clinical Hospital
79010 Lviv
UkraineRekrutierend» Google-Maps
CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC SI Dnipropetrovsk MA of MOHU Ch of Oncology and MR
49102 Dnipropetrovsk
UkraineRekrutierend» Google-Maps
Kyiv City Clinical Oncological Center
03115 Kyiv
UkraineRekrutierend» Google-Maps
Belfast City Hospital
BT9 7AB Belfast
United KingdomZurückgezogen» Google-Maps
Addenbrookes Hospital
CB2 0QQ Cambridge
United KingdomRekrutierend» Google-Maps
Western General Hospital
EH4 2XU Edinburgh
United KingdomRekrutierend» Google-Maps
St James Hospital; Dept of Oncology/Hematology
LS9 7TF Leeds
United KingdomAktiv, nicht rekrutierend» Google-Maps
Barts Hospital; Institute of Cancer
EC1M 6BQ London
United KingdomRekrutierend» Google-Maps
University College London NHS Foundation Trust
NW1 2PG London
United KingdomRekrutierend» Google-Maps
Royal Marsden Hospital - London
SW3 6JJ London
United KingdomRekrutierend» Google-Maps
Charing Cross Hospital
W6 8RF London
United KingdomRekrutierend» Google-Maps
Derriford Hospital
PL6 8BT Plymouth
United KingdomRekrutierend» Google-Maps
Royal Preston Hospital
PR2 9HT Preston
United KingdomRekrutierend» Google-Maps
Weston Park Hospital
S10 2SJ Sheffield
United KingdomRekrutierend» Google-Maps
Southampton University Hospitals NHS Trust
SO16 6YD Southampton
United KingdomRekrutierend» Google-Maps
Royal Marsden Hospital (Sutton)
SM2 5PT Sutton
United KingdomRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to

evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with

placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence

following cystectomy.

Ein-/Ausschlusskriterien

Inclusion Criteria for the Surveillance Phase:

- Histologically confirmed MIUC (also termed TCC) of the bladder

- TNM classification (based on AJCC Cancer Staging Manual, 8th Edition; Amin et al.

2016) at pathological examination of surgical resection specimen as follows: For

patients treated with prior NAC: tumor stage of ypT2-4a or ypN+ and M0. For patients

who have not received prior NAC: tumor stage of pT2-4a or pN+ and M0

- Surgical resection of MIUC of the bladder

- Patients who have received prior platinum-based NAC.

- Patients who have not received prior platinum-based NAC, have refused, are ineligible

("unfit") for cisplatin-based adjuvant chemotherapy, or will not receive based on

physicisan's decision.

- ctDNA assay developed based on tumor tissue specimen and matched normal DNA from

blood.

- Tumor PD-L1 expression per IHC that is evaluable by central testing of a

representative tumor tissue specimen.

- Absence of residual disease and absence of metastasis, as confirmed by a negative

baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan of the

pelvis, abdomen, and chest no more than 4 weeks prior to enrollment.

- Full recovery from cystectomy and enrollment within 24 weeks following cystectomy.

Minimum of 6 weeks must have elapsed from surgery.

Additional Inclusion Criteria for the Treatment Phase:

- Blood for plasma ctDNA sample evaluated to be ctDNA positive, defined as the presence

of two or more mutations out of the 16 mutations identified based on patient's WES

evaluable (ctDNA assay designability) report

- Absence of residual disease and absence of metastasis, as confirmed by a negative

baseline CT or MRI scan of the pelvis, abdomen, and chest no more than 28 days prior

to randomization, as assessed by the investigator

- ECOG Performance Status of <= 2

- Life expectancy >=12 weeks

- Adequate hematologic and end-organ function, investigator decision

- For women of childbearing potential: agreement to remain abstinent (refrain from

heterosexual intercourse) or use contraception and agreement to refrain from donating

eggs

General Medical Exclusion Criteria for the Surveillance Phase:

- Known PD-L1 IHC result for adjuvant therapy. The decision for the adjuvant therapy

should not be based on the PD-L1 IHC result. If a cap is in effect limiting enrollment

of PD-L1 negative patients, this exclusion criterion will not apply.

- Pregnancy or breastfeeding

- Positive test for HIV, with the following exception: Patients with a positive HIV test

at screening are eligible provided they are stable on antiretroviral therapy, have a

CD4 count >= 200/µL, and have an undetectable viral load

- Patients with active hepatitis B virus or hepatitis C. Patients with past HBV

infection or resolved HBV infection are eligible. A negative HBV DNA test must be

obtained in these patients prior to enrollment.

Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase

chain reaction is negative for HCV RNA.

- Active tuberculosis confirmed by a test performed within 3 months prior to treatment

initiation.

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to

chimeric or humanized antibodies or fusion proteins

- Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells

or any component of the atezolizumab formulation

- History of autoimmune disease. Patients with a history of autoimmune-related

hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for

this study. Patients with controlled Type I diabetes mellitus on a stable dose of

insulin regimen may be eligible for this study.

- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced

pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening

chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is

permitted.

- Significant cardiovascular disease, such as New York Heart Association cardiac disease

(Class II or greater), myocardial infarction within the previous 3 months, unstable

arrhythmias, or unstable angina

Cancer-Specific Exclusion Criteria for the Surveillance Phase:

- Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3

weeks prior to study enrollment

- Adjuvant chemotherapy or radiation therapy for UC following cystectomy

- Treatment with any other investigational agent or participation in another clinical

trial with therapeutic intent within 28 days or 5 half-lives of the drug, whichever is

longer, prior to enrollment

- Malignancies other than UC within 5 years prior to study enrollment

Additional Exclusion Criteria for the Treatment Phase:

- Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3

weeks prior to randomization to the treatment phase Hormone-replacement therapy or

oral contraceptives are allowed.

- Adjuvant chemotherapy or radiation therapy for UC following cystectomy

- Treatment with any other investigational agent or participation in another clinical

trial with therapeutic intent within 28 days or 5 half-lives of the drug, whichever is

longer, prior to randomization to the treatment phase

- Positive test for HIV, with the following exception: Patients with a positive HIV test

at screening are eligible provided they are stable on antiretroviral therapy, have a

CD4 count >= 200/μL, and have an undetectable viral load.

- Patients with active hepatitis B virus or hepatitis C

- Active tuberculosis confirmed by a test performed within 3 months prior to treatment

initiation

Studien-Rationale

Primary outcome:

1. Investigator-assessed DFS (Time Frame - Randomization up to first occurrence of DFS event (up to approximately 40 months)):
Investigator-assessed disease-free survival (DFS), defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following: Local (pelvic) recurrence of urothelial carcinoma (UC) (including soft tissue and regional lymph nodes) Urinary tract recurrence of UC (including all pathological stages and grades) Distant metastasis of UC Death from any cause



Secondary outcome:

1. Overall survival (OS) (Time Frame - Randomization up to death from any cause (up to approximately 10 years)):
Overall survival (OS), defined as the time from randomization to death from any cause.

2. Independent Review Facility (IRF)-Assessed DFS (Time Frame - Randomization up to first occurrence of DFS event (up to approximately 40 months))

3. Investigator-Assessed Disease-Specific Survival (Time Frame - Randomization to death from UC (up to approximately 10 years)):
Investigator-assessed disease-specific survival, defined as the time from randomization to death from UC per investigator assessment of cause of death.

4. Investigator-Assessed Distant Metastasis-Free Survival (Time Frame - Randomization to diagnosis of distant metastases or death from any cause (up to approximately 10 years)):
Investigator-assessed distant metastasis-free survival, defined as the time from randomization to the diagnosis of distant (i.e., non-locoregional) metastases or death from any cause.

5. Time to Confirmed Deterioration of Function and Health Related Quality of Life (HRQoL) (Time Frame - Randomization to participant's first score decrease of >=10 points from Baseline on EORTC QLQ-C30 physical function scale, role function scale, and the GHS/QoL Scale (up to approximately 10 years)):
Time to confirmed deterioration of function and health-related quality of life (HRQoL), defined as the time from randomization to the date of a participant's first score decrease of >= 10 points from baseline on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) physical function scale, role function scale, and the global health status (GHS)/QoL scale (separately), held for at least two consecutive time points or followed by death.

6. ctDNA Clearance (Time Frame - Baseline, Cycle 3 Day 1 or Cycle 5 Day 1 (each cycle is 28 days)):
ctDNA clearance, defined as the proportion of patients who are ctDNA positive at baseline and ctDNA negative at Cycle 3, Day 1 or Cycle 5, Day 1.

7. Percentage of Participants With Adverse Events (Time Frame - Baseline up to approximately 10 years)

8. Serum Concentration of Atezolizumab (Time Frame - At pre-defined intervals from first administration of study drug up to approximately 10 years)

9. Incidence of Anti-Drug Antibodies (ADAs) to Atezolizumab (Time Frame - Baseline up to approximately 10 years):
Incidence of anti-drug antibodies (ADAs) to atezolizumab after initiation of study treatment (postbaseline incidence).

10. Prevalence of ADAs to Atezolizumab (Time Frame - Baseline):
Prevalence of ADAs to atezolizumab at baseline.

Studien-Arme

  • Experimental: Arm A: Atezolizumab
    Atezolizumab will be administered intravenously at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
  • Placebo Comparator: Arm B: Placebo
    Placebo will be administered intravenously on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.

Geprüfte Regime

  • Atezolizumab (Tecentriq):
    Participants will receive 1680 mg intravenously every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
  • Placebo:
    Participants will receive placebo intravenously Q4W on Day 1 of each 28-day cycle

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.